Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

Merck KGaA said the deal will grow its U.S. presence and expand the reach of SpringWorks’ drugs, including one approved in February.

Germany’s Merck KGaA has agreed to acquire U.S. biotech SpringWorks Therapeutics for $3.9 billion. The acquisition, aimed at ...

Merck KGaA acquires SpringWorks Therapeutics, Inc. for $3.9B, boosting its pipeline with OGSIVEO & GOMEKLI. Click for more on ...

Germany’s Merck KGaA is paying $45 million upfront for rights to a potentially first-in-class drug for colorectal cancer (CRC) being developed by New York biotech Inspirna. The agreement gives ...

Recent health news highlights include Sandoz's criticism of EU drug pricing, a US-Mexico pact on pest control, advancements in cancer therapies, and significant corporate deals. Studies, policy ...

The killing of a veteran Filipino journalist in his home was a "heinous act" that was being investigated by police, the Philippines' Presidential Task Force on Media Security said on Wednesday. Juan ...

Protein Engineering Market IntroductionThe protein engineering market is rapidly evolving, driven by the need to develop proteins with improved functionality for a range of applications, including ...

Alphamab Oncology (stock code: 9966.HK) announced that the preclinical data on two novel bispecific antibody-drug conjugates (ADCs) JSKN021 and JSKN022 were presented as posters at the 2025 American ...